National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 57 of 66

COMPLETED Phase 1

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

NCT00020540
COMPLETED Phase 2

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

NCT00005949
COMPLETED Phase 2

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00014170
COMPLETED Phase 2

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

NCT00017394
COMPLETED Phase 2

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

NCT00017316
COMPLETED

Research in Skin Inflammation

NCT00026741
COMPLETED NA

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
TERMINATED Phase 1

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

NCT00012194
COMPLETED Phase 1

PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck

NCT00011778
COMPLETED Phase 1

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

NCT00011414
COMPLETED Phase 2

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
COMPLETED Phase 1

Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer

NCT00020410
COMPLETED Phase 1

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

NCT00020462
COMPLETED

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

NCT00026728
COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475
COMPLETED Phase 1

Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors

NCT00020488
COMPLETED Phase 1

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

NCT00016016
COMPLETED Phase 2

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

NCT00006436
COMPLETED

Natural History of Patients With Brain and Spinal Cord Tumors

NCT00009035
COMPLETED Phase 1

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

NCT00005576
COMPLETED Phase 2

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00004888
COMPLETED Phase 1

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

NCT00007917
COMPLETED Phase 2

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00020449
TERMINATED NA

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

NCT00005786
COMPLETED

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

NCT00006425
COMPLETED Phase 2

Arsenic Trioxide in Treating Patients With Urothelial Cancer

NCT00009867
COMPLETED Phase 1

Immunotoxin Therapy in Treating Patients With Advanced Cancer

NCT00006981
COMPLETED Phase 1

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

NCT00010192
TERMINATED Phase 2

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

NCT00009919
TERMINATED Phase 1

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808
TERMINATED Phase 1

Benzoylphenylurea in Treating Patients With Advanced Cancer

NCT00010205
TERMINATED Phase 1

Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00005856
TERMINATED Phase 3

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00009906
COMPLETED

Late Effects of Treatment for Sarcomas in Children

NCT00006515
COMPLETED Phase 1

Capravirine to Treat Children With HIV Infection

NCT00006519
COMPLETED Phase 3

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00006363
COMPLETED Phase 1

Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

NCT00007956
COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

NCT00020397
COMPLETED Phase 1

BMS-247550 in Treating Patients With Advanced Cancers

NCT00006221
COMPLETED Phase 2

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00009971
COMPLETED Phase 2

Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors

NCT00006450
TERMINATED Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

NCT00009958
COMPLETED

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study

NCT00006421
COMPLETED Phase 1

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00020332
COMPLETED Phase 2

Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00006389
COMPLETED NA

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

NCT00006243
COMPLETED Phase 2

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

NCT00005862
COMPLETED Phase 2

Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

NCT00006486
COMPLETED Phase 2

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00006942
COMPLETED Phase 2

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00006089
← Previous Page 57 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.